On May 14, 2025, Editas Medicine, Inc. announced new data showing effective gene editing levels of up to 48% in hematopoietic stem cells using their proprietary lipid nanoparticles, surpassing the therapeutic threshold of 25%. This filing provides insight into their advancements in gene therapy for conditions requiring stem cell editing.